Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.83 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.43 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.43 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.43 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458793 | 0.97 | KRAS (0.78) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL30147438 | 0.92 | KRAS (0.70) | KRASCRBN | |
| SCHEMBL18133981 | 0.91 | KRAS (0.83) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL21458796 | 0.91 | KRAS (0.69) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL21471940 | 0.91 | KRAS (1.00) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL30244442 | 0.90 | KRAS (0.84) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL21458690 | 0.90 | KRAS (0.84) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL21472006 | 0.90 | KRAS (0.83) | KRASCRBNEGFRHMOX2CRYZ | |
| SCHEMBL21472341 | 0.89 | KRAS (0.66) | KRASCRBN | |
| SCHEMBL16646985 | 0.89 | KRAS (0.82) | KRASCRBNEGFRHMOX2CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885EGFR 2207/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885EGFR 2207/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | KRAS 289/4885CRBN 1/4885EGFR 1180/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885EGFR 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.